Publications by authors named "J Raghul"

Claim this Profile
E
Enhanced anticancer efficacy of histone deacetyl inhibitor, suberoylanilide hydroxamic acid, in combination with a phosphodiesterase inhibitor, pentoxifylline, in human cancer cell lines and in-vivo tumor xenografts.
Saranya Nidhyanandan, Boreddy S Thippeswamy, Kottapalli B Chandrasekhar, Neetinkumar D Reddy, Nagaraj M Kulkarni, Jayaprakash Raghul

Anticancer Drugs· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Altered pharmacokinetics of rosiglitazone in a mouse model of non-alcoholic fatty liver disease.
Nagaraj M Kulkarni, Sandeep Malampati, Mahamad Yunnus A Mahat, S Chandrasekaran, J Raghul

Drug Metab Pers Ther· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel animal model of metabolic syndrome with non-alcoholic fatty liver disease and skin inflammation.
Nagaraj M Kulkarni, Mallikarjun S Jaji, Pranesha Shetty, Yeshwant V Kurhe, Shilpee Chaudhary, J Raghul

Pharm Biol· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Topical atorvastatin ameliorates 12-O-tetradecanoylphorbol-13-acetate induced skin inflammation by reducing cutaneous cytokine levels and NF-κB activation.
Nagaraj M Kulkarni, Milind M Muley, Mallikarjun S Jaji, G Vijaykanth, J Raghul

Arch Pharm Res· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tubastatin, a selective histone deacetylase 6 inhibitor shows anti-inflammatory and anti-rheumatic effects.
Santosh Vishwakarma, Lakshmi R Iyer, Milind Muley, Pankaj Kumar Singh, Arun Shastry, J Raghul

Int Immunopharmacol· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis